[go: up one dir, main page]

BRPI0507094A - métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo - Google Patents

métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo

Info

Publication number
BRPI0507094A
BRPI0507094A BRPI0507094-5A BRPI0507094A BRPI0507094A BR PI0507094 A BRPI0507094 A BR PI0507094A BR PI0507094 A BRPI0507094 A BR PI0507094A BR PI0507094 A BRPI0507094 A BR PI0507094A
Authority
BR
Brazil
Prior art keywords
oltipraz
low crystallinity
preparation
methods
amorphous
Prior art date
Application number
BRPI0507094-5A
Other languages
English (en)
Inventor
Cheong Weon Cho
Kyoung Rae Kang
Sang Ho Lee
Jeong Ku
Taekrho Kim
Sung Hak Lee
Jae Mook Choi
Jun Hee Cheon
Tae Kun An
Hyun Jung Park
Eun Kyung Jeon
Kwang Do Choi
Jee Woong Lim
Kwang Hee Hong
Hyesuk Hong
Il Hwan Kim
Tae Hyoung Kim
Nak Hyun Choi
Young Hoon Kim
Kyu Jeong Yeon
Hearan Suh
Hae Tak Jin
Jinwan Kim
In Ki Min
Original Assignee
Cj Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Corp filed Critical Cj Corp
Publication of BRPI0507094A publication Critical patent/BRPI0507094A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D5/00—Sheets united without binding to form pads or blocks
    • B42D5/04—Calendar blocks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D15/00—Printed matter of special format or style not otherwise provided for
    • B42D15/02—Postcards; Greeting, menu, business or like cards; Letter cards or letter-sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo é provido um método de preparação de oltipraz de baixa cristalinidade ou oltipraz amorfo. O método inclui: obter uma solução misturada que contém oltipraz e um polimero solúvel em água ou um polímero insolúvel em água num solvente, sendo o solvente um solvente orgânico ou água purificada; e fazer uma dispersão sólida do oltipraz no polímero. Na dispersão sólida, a solução misturada pode ser seca por spray usando um secador de spray ou granulada usando um granulador de leito fluido.
BRPI0507094-5A 2004-01-27 2005-01-27 métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo BRPI0507094A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040005000A KR100629771B1 (ko) 2004-01-27 2004-01-27 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
PCT/KR2005/000232 WO2005070397A1 (en) 2004-01-27 2005-01-27 Method of preparing low-crystallinity oltipraz or amorphous oltipraz

Publications (1)

Publication Number Publication Date
BRPI0507094A true BRPI0507094A (pt) 2007-06-19

Family

ID=36950958

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507094-5A BRPI0507094A (pt) 2004-01-27 2005-01-27 métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo

Country Status (12)

Country Link
US (1) US20050163855A1 (pt)
EP (1) EP1737430A1 (pt)
JP (1) JP2007519714A (pt)
KR (1) KR100629771B1 (pt)
CN (1) CN1921837A (pt)
AU (1) AU2005206063B2 (pt)
BR (1) BRPI0507094A (pt)
CA (1) CA2554588A1 (pt)
NO (1) NO20063571L (pt)
RU (1) RU2342926C2 (pt)
WO (1) WO2005070397A1 (pt)
ZA (1) ZA200607118B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2009118356A2 (en) * 2008-03-25 2009-10-01 Formac Pharmaceuticals N.V. Preparation method for solid disupersions
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
WO2018047002A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
WO2018047013A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
AU2017323504A1 (en) * 2016-09-12 2019-05-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
EP3509641A1 (en) * 2016-09-12 2019-07-17 ST IP Holding AG Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
EP3762104A2 (en) * 2018-03-07 2021-01-13 ST IP Holding AG Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1851571A (en) * 1930-01-31 1932-03-29 Franklin Dev Corp Means for retarding spinning of automobile transmission gears during gear shifting operation
EP0617612B1 (en) * 1991-12-18 1997-09-10 Warner-Lambert Company A process for the preparation of a solid dispersion
DE60121426T2 (de) * 2000-03-02 2007-02-22 Kim, Sang Geon Pharmazeutische zusammensetzung zur behandlung und prävention der leberfibrose und-zirrhose
US20030191137A1 (en) * 2000-04-07 2003-10-09 Sang-Geon Kim Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
KR100629771B1 (ko) 2006-09-28
AU2005206063A1 (en) 2005-08-04
RU2006130733A (ru) 2008-03-10
KR20050077381A (ko) 2005-08-02
AU2005206063B2 (en) 2008-10-02
EP1737430A1 (en) 2007-01-03
NO20063571L (no) 2006-10-19
JP2007519714A (ja) 2007-07-19
US20050163855A1 (en) 2005-07-28
ZA200607118B (en) 2008-04-30
RU2342926C2 (ru) 2009-01-10
WO2005070397A1 (en) 2005-08-04
CA2554588A1 (en) 2005-08-04
AU2005206063A2 (en) 2005-08-04
CN1921837A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0507094A (pt) métodos de preparação e de uso de oltipraz de baixa cristalinidade ou oltipraz amorfo
RS52891B (en) GASTRORE-RESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINE
BRPI0516772A (pt) formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
DE69906269D1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
BRPI0509659A (pt) composições de polìmero de dispersão lìquida, sua preparação e uso
WO2009006397A3 (en) Electrode systems and methods comprising a hydrophilic swollen polymer
FR2877207B1 (fr) Dispositif de resection de tissus organiques utilise notamment en urologie ou en hysteroscopie
BR0113494A (pt) Processo para a preparação de uma formulação sólida herbicida, e, uso de uma formulação sólida herbicida
AR052980A1 (es) Preparacion de dispersiones polimericas de etileno - acido acrilico neutralizadas y uso en medios de impresion para mejorar la adhesion de pigmento organico digital
CN103693747B (zh) 应用于生态浮床的无机材料载体
BR0009578A (pt) Composições de polìmero de dispersão lìquido, sua preparação e seu uso
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
HRP20060418A2 (en) Material solubiliser reactor for hydrolysis and/or wet fermentation and waste treatment plant with such a solubiliser and reactor
BRPI0814478A8 (pt) método e sistema para aumentar o grau de atividade de asparaginase em uma solução e método para fabricação de uma solução estável de enzima a partir de água potável
WO2008081938A1 (ja) 耐熱性ビオチン結合性タンパク質の利用法、および当該タンパク質が結合した固体担体
BRPI0510070A (pt) processo para a fabricação de agentes de tingimento azo altamente puros
BRPI0611813A2 (pt) mÉtodo de uso de antagonistas de zonulina para prevenir a perda de ou para regenerar cÉlulas pancreÁticas
BRPI0519862A2 (pt) método e produto
WO2006125501A3 (en) A coating composition
WO2002030477A8 (en) Use of n-halamine biocidal polymer for odor control
MY141967A (en) Process for the preparation of an artificial latex
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
NZ587127A (en) Sub-micron compositions
PT1141148E (pt) Composicao de revestimento
EA200501698A1 (ru) Противовспенивающие композиции

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CJ CHEILJEDANG CORPORATION (KR)

Free format text: TRANSFERIDO DE: CJ CORPORATION

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.